---
schema_version: "secwatch.filing_event.v1"
accession: "0001688757-24-000056"
form_type: "8-K"
ticker: "ESTA"
cik: "0001688757"
company_name: "ESTABLISHMENT LABS HOLDINGS INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T11:11:21.750310+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Establishment Labs reports Q1 revenue down 20% YoY; narrows operating loss sequentially; reaffirms 2024 guidance

## Summary
- Q1 2024 revenue $37.2M (down 20% YoY from $46.5M); net loss $16.2M vs $11.9M loss in Q1 2023.
- Adjusted EBITDA loss improved to $3.7M from $17.3M in Q4 2023; operating loss $8.8M vs $22.1M in Q4 2023.
- Cash balance $73.0M, up $32.9M from Dec 31, 2023 due to private placement; 2024 revenue guidance reaffirmed at $174M-$184M.
- Company presented 4-year Motiva US IDE study data with low capsular contracture/rupture rates; expects FDA approval in 2024.
- Launched Motiva implants in China and Flora tissue expander in US; cost reduction initiatives lowered SG&A and R&D expenses.

## SEC filing metadata
- accession: 0001688757-24-000056
- form_type: 8-K
- ticker: ESTA
- cik: 0001688757
- company_name: ESTABLISHMENT LABS HOLDINGS INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1688757/000168875724000056/0001688757-24-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1688757/000168875724000056/esta-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001688757-24-000056
- JSON: https://secwatch.observer/filing/0001688757-24-000056.json
- Plain text: https://secwatch.observer/filing/0001688757-24-000056.txt

## Key facts
- Earnings Releases
  ESTABLISHMENT LABS HOLDINGS INC. reported the three months ended March 31, 2024 results: revenue $37.2 million, net income $16.2 million. Guidance reaffirmed.
  - Period: the three months ended March 31, 2024
  - Revenue: $37.2 million
  - Net income: $16.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: and reconstruction, today announced financial results for the first quarter ended March 31, 2024. First Quarter Highlights and Outlook • First quarter worldwide revenue of $37.2 million. • 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from Motiva Implants ® in the United States,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1688757/000168875724000056/0001688757-24-000056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.